Tag: dual agonist

Browse all articles tagged with “dual agonist”.

4 articles

Tirzepatide: The Dual GIP/GLP-1 Receptor Agonist Reshaping Metabolic Research

A comprehensive research overview of tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro and Zepbound. Explore its mechanism, SURMOUNT and SURPASS trial data, $16.5B revenue trajectory, and how it compares to semaglutide.

2026-03-09·17 min read

TirzepatideGIPGLP-1dual agonistMounjaroZepboundmetabolic healthweight management

Metabolic Health

What Is Tirzepatide? A Research Overview

Tirzepatide is a dual GIP/GLP-1 receptor agonist that represents a new class of incretin-based therapeutics for type 2 diabetes and obesity management.

2026-02-28·6 min read

TirzepatideGIPGLP-1dual agonistweight managementmetabolic healthdiabetes

Metabolic Health

Survodutide: The Dual Glucagon/GLP-1 Agonist Targeting Liver Disease

A research overview of survodutide, the investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim being developed for obesity and NASH/MASH, with a focus on its hepatic fat reduction potential.

2026-01-25·10 min read

SurvodutideglucagonGLP-1dual agonistNASHMASHliver diseaseBoehringer Ingelheimmetabolic health

Metabolic Health

Mazdutide: The Dual GLP-1/Glucagon Agonist From Innovent Biologics

A research overview of mazdutide (IBI362), the dual GLP-1/glucagon receptor agonist developed by Innovent Biologics for the Chinese and global markets, with Phase 3 data showing significant weight loss and metabolic improvements.

2026-01-20·9 min read

MazdutideGLP-1glucagondual agonistInnovent Biologicsobesitymetabolic healthChina

←Back to blog

For informational purposes only. Not medical advice. Always consult with qualified healthcare professionals.